Paul Stoffels’ new Armed Cell Therapeutics buys Lakefront’s (ex-Galapagos) preclinical CAR-T work for $9M upfront, $230M in ...

OMass has raised one of the largest private financings for a UK biotech in recent years as it seeks to follow in the ...

Sanofi's new R&D chief said on Wednesday Western drugmakers cannot ignore China's accelerating innovation and should consider ...

FDA launches Rare Disease Framework Initiative to tailor reviews by disease, with a stakeholder meeting set for Oct. 28.

Verastem Oncology announced VS-7375 data showing 41% response rate in pancreatic cancer, raised $250M, and CEO Dan Paterson ...

Ultragenyx sold 2 PRVs for $203M and $210M; Biomea's BMF-650 showed modest weight loss; Skyhook Bio shutters; Altay raises ...

Arrowhead Pharmaceuticals' ARO-MAPT subcutaneous injection reduced tau protein by up to 85% in healthy volunteers, ...

Gilead pays Vir Biotechnology $65M upfront plus $25M investment for 3 T cell engager solid tumor therapies. Deal includes ...

GSK will make up to 1,217 workers redundant from its sites in Belgium as part of the cost-cutting initiative CEO Luke Miels ...

Ter­re­mo­to Bio­sciences has se­cured $108 mil­lion to fund first-in-hu­man test­ing for its next-gen­er­a­tion small mol­e­cule drugs. The South San Fran­cis­co, CA biotech, whose name trans­lates ...

The head of the FDA of­fice that helps de­ter­mine or­phan drug des­ig­na­tions has been re­as­signed and is no longer in the role, an ad­min­is­tra­tion of­fi­cial con­firmed to End­points News.

Beam Therapeutics shared Phase 1/2 data on BEAM-301 for GSDIa; Pfizer partnered with Enodia on Sec61 inhibitors for $500M+; ...